Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

RecruitingPhase 1

NCT06544265

SynKIR-310 for Relapsed/Refractory B-NHL

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administe…

United States36 participantsStarted 2024-11-01

Treatment: SynKIR-310

RecruitingPhase 2

NCT06834373

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C…

This phase II trial tests the effectiveness of golcadomide and rituximab as bridging treatment before chimeric antigen receptor (CAR) T-cell therapy in patients…

United States41 participantsStarted 2025-04-02

Treatment: Biospecimen Collection, Bone Marrow Aspiration

All recent trials (8 shown)

Active — Not RecruitingPhase 2/3

NCT04799275

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diff…

This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cycloph…

United States422 participantsStarted 2021-05-20

Treatment: Biospecimen Collection, Computed Tomography

Active — Not RecruitingPhase 2

NCT05507541

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

This phase II trial tests the safety, side effects, and best dose of TTI-621 (closed to enrollment) or TTI-622 in combination with pembrolizumab in treating pat…

United States10 participantsStarted 2023-04-19

Treatment: Biospecimen Collection, Computed Tomography

Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

SynKIR-310 for Relapsed/Refractory B-NHL

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C…

All recent trials (8 shown)

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diff…

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

SynKIR-310 for Relapsed/Refractory B-NHL

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C…

All recent trials (8 shown)

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diff…

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Maligna…

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphom…

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated…